Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours
NCT01668550 · Cancer Research UK · PHASE1 · terminated · last registry update 2018-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Single agent phase completed, insufficient supportive preclinical data to proceed with combination phase” | – | Registry record, Cancer Research UK |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-02-04Phase 3 first posted: Institut du Cancer de Montpellier - Val d'Aurelle, Regorafenib + Irinotecan (NCT03829462)
- 2018-12-21Phase 3 first posted: Institut National de la Santé Et de la Recherche Médicale, France, Nilotinib + Ceritinib (NCT03784014)
- 2018-10-29Phase 3 first posted: Il-Yang Pharm. Co., Ltd., Radotinib + Imatinib (NCT03722420)
- 2018-09-17Phase 3 first posted: Deciphera Pharmaceuticals, LLC, Ripretinib + Sunitinib (NCT03673501)
- 2018-08-15Phase 3 first posted: Cordgenics, LLC, Chemotherapy (NCT03632135)
- 2018-07-17Phase 3 first posted: Takeda, Ponatinib + Imatinib (NCT03589326)
- 2018-03-09Phase 3 first posted: Il-Yang Pharm. Co., Ltd., Radotinib HCl (NCT03459534)
- 2018-01-05Results posted on the registry: Bristol-Myers Squibb, Dasatinib (NCT00777036)
- 2017-04-26Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Cytarabine (NCT00792948)
- 2017-04-18Phase 3 first posted: St. Jude Children's Research Hospital, Prednisone + Vincristine (NCT03117751)
- 2017-04-13Phase 3 first posted: Incyte Corporation, Ruxolitinib + Extracorporeal photopheresis (ECP) (NCT03112603)
- 2017-04-10Phase 3 first posted: Novartis Pharmaceuticals, Asciminib + Bosutinib (NCT03106779)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision